These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

262 related articles for article (PubMed ID: 6403466)

  • 41. Normal bactericidal capacity against Neisseria meningitidis in serum from a patient with a hemolytically inactive complement factor 8 (C8).
    Strate M; Olsen H; Teisner B; Brandslund I
    Acta Pathol Microbiol Immunol Scand B; 1983 Dec; 91(6):431-4. PubMed ID: 6424405
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Protection against group B meningococcal disease. I. Comparison of group-specific and type-specific protection in the chick embryo model.
    Frasch CE; Parkes L; McNelis RM; Gotschlich EC
    J Exp Med; 1976 Aug; 144(2):319-29. PubMed ID: 822114
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Specificity of the immune response to the group B polysaccharide of Neisseria meningitidis.
    Lifely MR; Esdaile J
    Immunology; 1991 Nov; 74(3):490-6. PubMed ID: 1722773
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Meningococcal Serogroup A, B, C, W, X, and Y Serum Bactericidal Antibody Assays.
    Lucidarme J; Louth J; Townsend-Payne K; Borrow R
    Methods Mol Biol; 2019; 1969():169-179. PubMed ID: 30877677
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Immunity to Neisseria meningitidis group B in adults despite lack of serum bactericidal antibody.
    Welsch JA; Granoff D
    Clin Vaccine Immunol; 2007 Dec; 14(12):1596-602. PubMed ID: 17913865
    [TBL] [Abstract][Full Text] [Related]  

  • 46. NZB mouse system for production of monoclonal antibodies to weak bacterial antigens: isolation of an IgG antibody to the polysaccharide capsules of Escherichia coli K1 and group B meningococci.
    Frosch M; Görgen I; Boulnois GJ; Timmis KN; Bitter-Suermann D
    Proc Natl Acad Sci U S A; 1985 Feb; 82(4):1194-8. PubMed ID: 3919387
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Dot-immunobinding assay with a monoclonal antibody for detection of group B meningococcal antigen.
    Coll P; Borche L; Ausina V; Mirelis B; Prats G
    Eur J Clin Microbiol; 1986 Feb; 5(1):44-6. PubMed ID: 3084244
    [No Abstract]   [Full Text] [Related]  

  • 48. Epitopes recognized by a nonautoreactive murine anti-N-propionyl meningococcal group B polysaccharide monoclonal antibody.
    Moe GR; Dave A; Granoff DM
    Infect Immun; 2005 Apr; 73(4):2123-8. PubMed ID: 15784554
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Comparison of passive hemagglutination, bactericidal activity, and radioimmunological methods in measuring antibody responses to Neisseria meningitidis group A capsular polysaccharide vaccine.
    Käyhty H
    J Clin Microbiol; 1980 Aug; 12(2):256-63. PubMed ID: 6785306
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Sialic acid of group B Neisseria meningitidis regulates alternative complement pathway activation.
    Jarvis GA; Vedros NA
    Infect Immun; 1987 Jan; 55(1):174-80. PubMed ID: 3098684
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Measurement of antibodies against meningococcal capsular polysaccharides B and C in enzyme-linked immunosorbent assays: towards an improved surveillance of meningococcal disease.
    Andersen J; Berthelsen L; Lind I
    Clin Diagn Lab Immunol; 1997 May; 4(3):345-51. PubMed ID: 9144375
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Bactericidal antibody is the immunologic surrogate of protection against meningococcal disease.
    Frasch CE; Borrow R; Donnelly J
    Vaccine; 2009 Jun; 27 Suppl 2():B112-6. PubMed ID: 19464093
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Safety and immunogenicity of meningococcal A and C polysaccharide conjugate vaccine in adults.
    Anderson EL; Bowers T; Mink CM; Kennedy DJ; Belshe RB; Harakeh H; Pais L; Holder P; Carlone GM
    Infect Immun; 1994 Aug; 62(8):3391-5. PubMed ID: 8039909
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Evaluation of the level of antibodies to purified meningococcal antigens].
    Kuznetsova EM; Borisenko IuV; Tsvetkova NV
    Zh Mikrobiol Epidemiol Immunobiol; 1988 Jan; (1):65-8. PubMed ID: 3129887
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Murine immune response to the Neisseria meningitidis group C capsular polysaccharide. II. Specificity.
    Rubinstein LJ; Stein KE
    J Immunol; 1988 Dec; 141(12):4357-62. PubMed ID: 3143763
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Safety and immunogenicity of group Y and group W135 meningococcal capsular polysaccharide vaccines in adults.
    Griffiss JM; Brandt BL; Altieri PL; Pier GB; Berman SL
    Infect Immun; 1981 Dec; 34(3):725-32. PubMed ID: 6800954
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Protection against Escherichia coli K1 infection in newborn rats by antibody to K1 capsular polysaccharide antigen.
    Bortolussi R; Ferrier P
    Infect Immun; 1980 Apr; 28(1):111-7. PubMed ID: 6769816
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Selection of an immunogenic peptide mimic of the capsular polysaccharide of Neisseria meningitidis serogroup A using a peptide display library.
    Grothaus MC; Srivastava N; Smithson SL; Kieber-Emmons T; Williams DB; Carlone GM; Westerink MA
    Vaccine; 2000 Jan; 18(13):1253-63. PubMed ID: 10649627
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Issues surrounding standardization of meningococcal group W135 serology.
    Balmer P; Borrow R
    Vaccine; 2007 Sep; 25 Suppl 1():A63-8. PubMed ID: 17544550
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Specificity of antibodies to O-acetyl-positive and O-acetyl-negative group C meningococcal polysaccharides in sera from vaccinees and carriers.
    Arakere G; Frasch CE
    Infect Immun; 1991 Dec; 59(12):4349-56. PubMed ID: 1937795
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.